Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devasta...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 15; no. 12; p. 3126
Main Authors Plachouri, Kerasia-Maria, Florou, Vaia, Georgiou, Vasileios, Georgiou, Sophia
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 09.06.2023
MDPI
Subjects
Analysis
Antimitotic agents
Antineoplastic agents
Cancer
Care and treatment
Cell growth
Chemotherapy
Complications and side effects
Dermatitis
Development and progression
Immune checkpoint inhibitors
Immunology
Immunotherapy
Kinases
Malignancy
Melanoma
Metastases
Mutation
Oncology, Experimental
Patients
Proteins
Pruritus
Psoriasis
Quality of life
Review
Side effects
Skin
Skin cancer
Squamous cell carcinoma
Toxicity
targeted therapy
basal cell carcinoma
melanoma
cutaneous side effects
immune checkpoint inhibitors
squamous cell carcinoma
Online AccessGet full text

Cover

Abstract The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
AbstractList Cutaneous side effects are among the most frequently reported adverse reactions of modern dermato-oncological therapies, such as immune checkpoint inhibitors and targeted therapies. This study aims to provide a detailed overview of the cutaneous toxicity profile of these treatments to facilitate physicians' early recognition of these side effects. Furthermore, we aim to accentuate the need for a dermatological evaluation of the affected patients, as it can significantly affect the patient's quality of life and the decision to continue treatment. The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
Simple SummaryCutaneous side effects are among the most frequently reported adverse reactions of modern dermato-oncological therapies, such as immune checkpoint inhibitors and targeted therapies. This study aims to provide a detailed overview of the cutaneous toxicity profile of these treatments to facilitate physicians’ early recognition of these side effects. Furthermore, we aim to accentuate the need for a dermatological evaluation of the affected patients, as it can significantly affect the patient’s quality of life and the decision to continue treatment.AbstractThe advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
Cutaneous side effects are among the most frequently reported adverse reactions of modern dermato-oncological therapies, such as immune checkpoint inhibitors and targeted therapies. This study aims to provide a detailed overview of the cutaneous toxicity profile of these treatments to facilitate physicians' early recognition of these side effects. Furthermore, we aim to accentuate the need for a dermatological evaluation of the affected patients, as it can significantly affect the patient's quality of life and the decision to continue treatment.
Audience Academic
Author Florou, Vaia
Georgiou, Vasileios
Georgiou, Sophia
Plachouri, Kerasia-Maria
AuthorAffiliation 3 School of Medicine, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece
1 Dermatology Department, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece; georgiou@med.upatras.gr
2 Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 841112, USA
AuthorAffiliation_xml – name: 2 Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 841112, USA
– name: 1 Dermatology Department, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece; georgiou@med.upatras.gr
– name: 3 School of Medicine, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece
Author_xml – sequence: 1
  givenname: Kerasia-Maria
  surname: Plachouri
  fullname: Plachouri, Kerasia-Maria
  organization: Dermatology Department, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece
– sequence: 2
  givenname: Vaia
  surname: Florou
  fullname: Florou, Vaia
  organization: Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 841112, USA
– sequence: 3
  givenname: Vasileios
  surname: Georgiou
  fullname: Georgiou, Vasileios
  organization: School of Medicine, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece
– sequence: 4
  givenname: Sophia
  surname: Georgiou
  fullname: Georgiou, Sophia
  organization: Dermatology Department, University General Hospital of Patras, University of Patras, 265 04 Rio, Greece
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37370736$$D View this record in MEDLINE/PubMed
BookMark eNptUs9vFCEYJabG1tqzN0Pixcu2DMzAcjLNWrVJG01cz4SBj1maGViBqel_L82utW2EA-T73nvfj7zX6CDEAAi9bcgpY5KcGR0MpNx0DWUN5S_QESWCLjiX7cGj_yE6yfmG1MNYI7h4hQ6ZYIIIxo_QdjUXHSDOGf_wFvCFc2BKxtHh62ghBbzWaYACFq83kPT2Dutg8eU0zSGWfcQH_F0XD6ESf_uywZ8gTbrEMQ7e6BFf69EPoXbrIb9BL50eM5zs32P08_PFevV1cfXty-Xq_Gph2qUsC1s7F1YC7QxlwvXWUNcx0nWmo1QSq-2SSN2LRtJeC2I4rxnXcqd7Romm7Bh93Olu534Ca2pzSY9qm_yk052K2qunmeA3aoi3qiFUctawqvBhr5DirxlyUZPPBsZxty9Fl4zUsoKSCn3_DHoT5xTqfBVFpViSjrf_UIMeQfngYi1s7kXVuehaKTrORUWd_gdVr4XJm-oA52v8CeFsRzAp5pzAPQzZEHVvFPXMKJXx7vFuHvB_bcH-AGPDvFI
CitedBy_id crossref_primary_10_3390_cancers16061226
Cites_doi 10.1158/2326-6066.CIR-14-0134
10.5301/tj.5000625
10.1111/1756-185X.13076
10.1371/journal.pone.0160221
10.1186/s40425-016-0151-z
10.1136/jitc-2021-002879
10.1111/j.1365-2133.2012.11155.x
10.1001/jamadermatol.2017.4421
10.1001/jamadermatol.2013.7919
10.1111/ceo.13651
10.1001/jamadermatol.2015.5210
10.1136/annrheumdis-2016-210820
10.1007/s00281-015-0539-8
10.1111/dth.14871
10.1001/jamadermatol.2015.2707
10.3389/fmed.2019.00249
10.1186/s40425-018-0475-y
10.1001/jamadermatol.2017.2106
10.1056/NEJMc1113752
10.1002/cam4.350
10.1016/j.ejca.2017.03.026
10.1200/JCO.2015.63.7421
10.1016/j.jdcr.2016.11.002
10.1111/1346-8138.13520
10.1200/JCO.2013.53.0105
10.1136/annrheumdis-2016-209595
10.1186/s40425-016-0157-6
10.1111/cup.12876
10.2340/00015555-2212
10.1186/s40425-018-0323-0
10.1016/j.jaad.2014.09.002
10.1097/CMR.0000000000000261
10.1056/NEJMoa1103782
10.1016/j.jtho.2018.04.031
10.1097/CCO.0000000000000290
10.1001/jamadermatol.2014.2455
10.1097/CJI.0000000000000191
10.1200/JCO.2016.71.9476
10.1007/s10637-010-9567-3
10.1016/S1470-2045(12)70489-8
10.1016/j.jtho.2019.09.119
10.1056/NEJMoa1112302
10.1001/jamadermatol.2015.1745
10.1016/j.jaad.2013.01.012
10.1097/CMR.0b013e3283570792
10.1634/theoncologist.2014-0422
10.1111/jdv.16894
10.1016/j.jaad.2012.02.010
10.1038/sj.jid.5701155
10.1016/j.jdcr.2016.06.004
10.1007/s11864-016-0434-0
10.1111/cup.12666
10.1111/cup.12858
10.1016/S1470-2045(16)30098-5
10.1093/annonc/mdp325
10.1186/s12885-017-3313-6
10.20344/amp.12424
10.1634/theoncologist.2019-0250
10.1158/1078-0432.CCR-15-1136
10.1097/DAD.0000000000000688
10.1016/S1470-2045(18)30497-2
10.1001/jamadermatol.2013.1798
10.1158/2326-6066.CIR-15-0123
10.1016/j.jaad.2014.04.013
10.1097/DAD.0000000000001276
10.1016/j.ejca.2021.06.031
10.2147/CMAR.S163391
10.1016/j.jdcr.2016.10.008
10.1016/j.jdcr.2018.11.017
10.1111/cup.13044
10.1001/jamadermatol.2017.0091
10.1016/j.jaad.2012.04.008
10.1016/j.jaad.2018.10.062
10.1001/jamadermatol.2015.1916
10.1007/s00520-014-2434-6
10.7573/dic.2022-3-8
10.1111/jdv.14284
10.1634/theoncologist.2012-0333
10.5826/dpc.1101a155
10.1158/1078-0432.CCR-15-2872
10.1093/annonc/mdv383
10.1177/1078155220906885
10.1016/j.jdcr.2016.05.002
10.3390/curroncol29040234
10.2217/fon-2016-0296
10.1371/journal.pone.0053745
10.1097/DAD.0b013e3182858142
10.1111/cup.12717
10.1097/DAD.0000000000000528
10.1001/archdermatol.2012.2649
10.1200/JCO.2011.41.1660
10.1016/j.jaad.2020.03.132
10.1016/j.jaad.2014.02.035
10.21873/invivo.11793
10.4103/JIPO.JIPO_11_18
10.1016/j.ejca.2016.02.025
10.1111/bjd.15237
10.1200/JCO.2015.66.1389
10.1007/s40257-017-0336-3
10.1056/NEJMoa1605943
10.3389/fmed.2019.00262
10.1093/annonc/mds292
10.1056/NEJMc1108651
10.1002/pbc.27682
10.1016/j.jdcr.2016.05.009
10.18632/oncotarget.2980
10.1111/bjd.13630
10.1001/jamadermatol.2014.3207
10.1056/NEJMoa2109970
10.1097/DAD.0000000000000281
10.1097/CJI.0b013e318247a4e7
10.1016/j.jdcr.2021.02.012
10.1007/s40257-018-0384-3
10.1016/j.jaad.2015.01.011
10.1001/jamadermatol.2016.2226
10.14694/EdBook_AM.2015.35.76
10.1016/j.jaad.2014.07.033
10.2340/00015555-2566
10.1200/JCO.2014.57.4756
10.1111/bjd.13200
10.1093/jjco/hyaa139
10.1001/jamadermatol.2017.0989
10.1016/j.jval.2019.09.308
10.1097/CMR.0000000000000127
10.1177/1203475420943260
10.3390/diagnostics11050747
10.1016/S0140-6736(16)32517-X
10.1177/1078155216674355
10.1056/NEJMoa1203421
10.1016/j.pharmthera.2013.11.011
10.1056/NEJMoa1504030
10.1056/NEJMoa1412690
10.1097/CJI.0000000000000121
10.1016/S0140-6736(16)32455-2
10.1056/NEJMoa1412082
10.1097/CMR.0000000000000017
10.1111/bjd.15354
10.1016/j.ad.2016.05.019
10.5070/D3274053158
10.1111/bjd.13058
10.1111/j.1755-148X.2012.01031.x
10.1016/j.jaad.2015.10.029
10.1056/NEJMoa1113713
10.1111/pde.14495
10.1111/jdv.14011
10.1111/apm.12658
10.25259/IJDVL_1306_20
10.1186/s40425-016-0123-3
10.1093/annonc/mdt015
10.1111/jdv.14143
10.1111/ced.13867
10.1016/j.jaad.2018.07.008
10.1007/s00520-017-3629-4
10.1016/j.jdcr.2021.05.002
10.1016/j.jdcr.2017.08.001
10.1016/j.currproblcancer.2016.12.001
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID NPM
AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers15123126
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
Biological Sciences
ProQuest research library
Biological Science Database
Research Library (Corporate)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID A754975667
10_3390_cancers15123126
37370736
Genre Journal Article
Review
GroupedDBID ---
3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
ABDBF
ABUWG
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
NPM
OK1
P6G
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RPM
TUS
AAYXX
AFPKN
CITATION
7T5
7TO
7XB
8FK
H94
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c489t-d6697d9e25c237fbdc2f53055c52290dad809ab7192ba70c665c5f46fab320a23
IEDL.DBID RPM
ISSN 2072-6694
IngestDate Tue Sep 17 21:30:04 EDT 2024
Sat Oct 26 01:18:49 EDT 2024
Thu Oct 10 18:09:32 EDT 2024
Thu Feb 22 23:55:16 EST 2024
Tue Nov 12 22:54:47 EST 2024
Fri Aug 23 01:16:25 EDT 2024
Wed Oct 16 00:38:05 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords targeted therapy
basal cell carcinoma
melanoma
cutaneous side effects
immune checkpoint inhibitors
squamous cell carcinoma
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c489t-d6697d9e25c237fbdc2f53055c52290dad809ab7192ba70c665c5f46fab320a23
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296313/
PMID 37370736
PQID 2829780564
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10296313
proquest_miscellaneous_2830665720
proquest_journals_2829780564
gale_infotracmisc_A754975667
gale_infotracacademiconefile_A754975667
crossref_primary_10_3390_cancers15123126
pubmed_primary_37370736
PublicationCentury 2000
PublicationDate 20230609
PublicationDateYYYYMMDD 2023-06-09
PublicationDate_xml – month: 6
  year: 2023
  text: 20230609
  day: 9
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Cancers
PublicationTitleAlternate Cancers (Basel)
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Jour (ref_83) 2016; 43
ref_94
Tawbi (ref_22) 2022; 386
Mattei (ref_124) 2013; 24
Jirka (ref_161) 2015; 24
Chen (ref_1) 2022; 29
Topalian (ref_82) 2014; 32
Lilly (ref_142) 2015; 151
Beck (ref_46) 2016; 4
ref_99
Weber (ref_20) 2017; 35
Yang (ref_162) 2015; 4
Akkus (ref_113) 2020; 26
Naqash (ref_11) 2019; 7
Mahil (ref_35) 2015; 38
Teulings (ref_70) 2015; 33
Vigarios (ref_78) 2017; 25
Tetzlaff (ref_101) 2017; 44
Dummer (ref_119) 2012; 366
Tetzlaff (ref_110) 2018; 6
Jackson (ref_77) 2014; 23
Totonchy (ref_39) 2016; 152
Yatim (ref_53) 2019; 6
Chu (ref_141) 2012; 67
Hwang (ref_153) 2017; 108
Joseph (ref_30) 2015; 3
Koelzer (ref_104) 2016; 4
Lu (ref_89) 2019; 5
Suozzi (ref_108) 2016; 2
Aasi (ref_165) 2013; 149
Bousquet (ref_115) 2017; 97
Carlberg (ref_152) 2020; 38
Lacouture (ref_24) 2014; 71
Sibaud (ref_56) 2016; 28
Yokota (ref_4) 2020; 50
Schaberg (ref_31) 2016; 43
Abdulkader (ref_41) 2017; 125
Postow (ref_66) 2015; 35
Shi (ref_25) 2016; 152
(ref_10) 2021; 35
Larkin (ref_19) 2015; 373
Peters (ref_58) 2017; 35
Dombi (ref_155) 2016; 375
Flaherty (ref_154) 2012; 367
Moreno (ref_145) 2013; 69
Pach (ref_100) 2021; 13
Collins (ref_80) 2017; 41
Luke (ref_6) 2015; 6
Puig (ref_158) 2022; 11
Geisler (ref_42) 2020; 83
Antonia (ref_62) 2016; 17
Smith (ref_150) 2008; 128
Pennock (ref_7) 2015; 20
Macdonald (ref_3) 2015; 72
Sibaud (ref_5) 2018; 19
Naidoo (ref_28) 2015; 26
Caplash (ref_164) 2019; 48
McNally (ref_54) 2021; 10
Anforth (ref_131) 2015; 25
Piraccini (ref_136) 2015; 72
Chen (ref_91) 2018; 10
Balagula (ref_148) 2011; 29
Manson (ref_68) 2018; 154
Dummer (ref_135) 2018; 19
ref_160
Krammer (ref_52) 2019; 6
Pintova (ref_114) 2013; 23
Damsky (ref_47) 2016; 2
Wolner (ref_67) 2018; 178
Sosman (ref_126) 2012; 366
Park (ref_140) 2014; 150
Anforth (ref_122) 2014; 36
Sanlorenzo (ref_118) 2014; 71
ref_84
Shaw (ref_147) 2013; 14
Coleman (ref_44) 2019; 80
Chapman (ref_16) 2011; 364
Clawson (ref_51) 2021; 34
Coustal (ref_97) 2021; 155
Sekulic (ref_17) 2012; 366
Uemura (ref_103) 2016; 4
Lomax (ref_107) 2017; 20
Yin (ref_60) 2017; 3
Boussemart (ref_120) 2013; 24
Matsumura (ref_38) 2016; 96
Chen (ref_26) 2012; 67
Kwong (ref_98) 2017; 153
Anforth (ref_123) 2014; 172
Rittmeyer (ref_74) 2017; 389
Siegel (ref_45) 2018; 79
Bs (ref_93) 2020; 59
Raschi (ref_92) 2019; 24
Saw (ref_86) 2017; 81
Carlos (ref_15) 2015; 151
Fife (ref_159) 2017; 13
Kwon (ref_55) 2017; 31
McDermott (ref_79) 2016; 34
Robert (ref_134) 2015; 372
Kwong (ref_14) 2016; 17
Hwang (ref_43) 2016; 74
Monfort (ref_144) 2012; 22
Song (ref_156) 2019; 66
Nakamura (ref_71) 2016; 44
Estenaga (ref_95) 2021; 88
Aliste (ref_143) 2016; 38
Zarbo (ref_73) 2016; 176
Alkeraye (ref_157) 2015; 172
Mathias (ref_61) 2019; 14
Cappelli (ref_112) 2016; 76
Cohen (ref_128) 2013; 6
Lacouture (ref_12) 2013; 18
Tetzlaff (ref_33) 2017; 39
Muntyanu (ref_8) 2020; 25
Gkiozos (ref_111) 2018; 13
Quaglino (ref_64) 2009; 21
Ai (ref_90) 2021; 9
Isoletta (ref_149) 2022; 35
Bonigen (ref_40) 2016; 31
Garje (ref_50) 2018; 41
Welborn (ref_105) 2018; 1
Thomas (ref_96) 2021; 13
Naidoo (ref_49) 2016; 4
Hofmann (ref_23) 2016; 60
Gooden (ref_18) 2019; 22
ref_116
Anforth (ref_127) 2012; 167
Dasanu (ref_76) 2016; 23
Curry (ref_27) 2016; 44
Champiat (ref_117) 2018; 77
Sinha (ref_138) 2019; 41
(ref_9) 2016; 2016
Roh (ref_121) 2014; 71
Sendagorta (ref_163) 2018; 4
Lacouture (ref_75) 2018; 19
Balar (ref_57) 2017; 389
Cotliar (ref_109) 2016; 2
Vivar (ref_87) 2017; 44
Anforth (ref_125) 2012; 25
Goldinger (ref_88) 2016; 22
Meneguzzo (ref_130) 2019; 34
Rivera (ref_69) 2017; 153
Patel (ref_151) 2015; 151
Sowerby (ref_48) 2017; 153
ref_106
Liu (ref_63) 2019; 44
Munoz (ref_102) 2014; 171
Hua (ref_65) 2016; 152
Nasca (ref_146) 2016; 15
Sibaud (ref_34) 2017; 31
Garrido (ref_139) 2015; 37
Sanlorenzo (ref_59) 2015; 151
Inno (ref_81) 2017; 103
Hwang (ref_85) 2016; 26
Guggina (ref_32) 2016; 3
Cavalieri (ref_137) 2017; 11
Chia (ref_36) 2016; 39
(ref_13) 2014; 142
Robert (ref_21) 2015; 372
Apalla (ref_2) 2021; 11
Gomes (ref_29) 2020; 33
Zimmer (ref_132) 2012; 30
Kim (ref_72) 2016; 22
Morita (ref_133) 2011; 365
Dulos (ref_37) 2012; 35
Haenssle (ref_129) 2012; 148
References_xml – volume: 3
  start-page: 18
  year: 2015
  ident: ref_30
  article-title: Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 Therapy
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0134
  contributor:
    fullname: Joseph
– volume: 103
  start-page: 405
  year: 2017
  ident: ref_81
  article-title: Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
  publication-title: Tumori J.
  doi: 10.5301/tj.5000625
  contributor:
    fullname: Inno
– volume: 20
  start-page: 1277
  year: 2017
  ident: ref_107
  article-title: Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis
  publication-title: Int. J. Rheum. Dis.
  doi: 10.1111/1756-185X.13076
  contributor:
    fullname: Lomax
– ident: ref_94
  doi: 10.1371/journal.pone.0160221
– volume: 4
  start-page: 47
  year: 2016
  ident: ref_104
  article-title: Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-016-0151-z
  contributor:
    fullname: Koelzer
– volume: 9
  start-page: e002879
  year: 2021
  ident: ref_90
  article-title: Nivolumab-associated DRESS in a genetic susceptible individual
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2021-002879
  contributor:
    fullname: Ai
– volume: 167
  start-page: 1153
  year: 2012
  ident: ref_127
  article-title: Cutaneous manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma
  publication-title: Br. J. Dermatol.
  doi: 10.1111/j.1365-2133.2012.11155.x
  contributor:
    fullname: Anforth
– volume: 154
  start-page: 113
  year: 2018
  ident: ref_68
  article-title: Hair Repigmentation with Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2017.4421
  contributor:
    fullname: Manson
– volume: 13
  start-page: e14387
  year: 2021
  ident: ref_96
  article-title: Dermatomyositis Flare with Immune Checkpoint Inhibitor Therapy for Melanoma
  publication-title: Cureus
  contributor:
    fullname: Thomas
– volume: 150
  start-page: 307
  year: 2014
  ident: ref_140
  article-title: Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2013.7919
  contributor:
    fullname: Park
– volume: 48
  start-page: 123
  year: 2019
  ident: ref_164
  article-title: Report of cutaneous side effects of vismodegib treatment
  publication-title: Clin. Exp. Ophthalmol.
  doi: 10.1111/ceo.13651
  contributor:
    fullname: Caplash
– volume: 152
  start-page: 590
  year: 2016
  ident: ref_39
  article-title: Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2015.5210
  contributor:
    fullname: Totonchy
– volume: 77
  start-page: 468
  year: 2018
  ident: ref_117
  article-title: Onset of connective tissue disease following an-ti-PD1/PD-L1 cancer immunotherapy
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2016-210820
  contributor:
    fullname: Champiat
– volume: 38
  start-page: 11
  year: 2015
  ident: ref_35
  article-title: Update on psoriasis immunopathogenesis and targeted immunotherapy
  publication-title: Semin. Immunopathol.
  doi: 10.1007/s00281-015-0539-8
  contributor:
    fullname: Mahil
– volume: 34
  start-page: e14871
  year: 2021
  ident: ref_51
  article-title: Pemphigus vulgaris flare in a patient treated with nivolumab
  publication-title: Dermatol. Ther.
  doi: 10.1111/dth.14871
  contributor:
    fullname: Clawson
– volume: 152
  start-page: 45
  year: 2016
  ident: ref_65
  article-title: Association of Vitiligo with Tumor Response in Patients with Metastatic Melanoma Treated with Pembrolizumab
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2015.2707
  contributor:
    fullname: Hua
– volume: 6
  start-page: 249
  year: 2019
  ident: ref_53
  article-title: Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa
  publication-title: Front. Med.
  doi: 10.3389/fmed.2019.00249
  contributor:
    fullname: Yatim
– volume: 7
  start-page: 4
  year: 2019
  ident: ref_11
  article-title: Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-018-0475-y
  contributor:
    fullname: Naqash
– volume: 153
  start-page: 1162
  year: 2017
  ident: ref_69
  article-title: Hair Repigmentation During Immuno-therapy Treatment with an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2017.2106
  contributor:
    fullname: Rivera
– volume: 366
  start-page: 480
  year: 2012
  ident: ref_119
  article-title: Ultraviolet A and Photosensitivity during Vemurafenib Therapy
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc1113752
  contributor:
    fullname: Dummer
– volume: 4
  start-page: 245
  year: 2015
  ident: ref_162
  article-title: Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds
  publication-title: Cancer Med.
  doi: 10.1002/cam4.350
  contributor:
    fullname: Yang
– volume: 81
  start-page: 237
  year: 2017
  ident: ref_86
  article-title: Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2017.03.026
  contributor:
    fullname: Saw
– volume: 34
  start-page: 833
  year: 2016
  ident: ref_79
  article-title: Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates from a Phase Ia Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.63.7421
  contributor:
    fullname: McDermott
– volume: 3
  start-page: 7
  year: 2016
  ident: ref_32
  article-title: Inverse lichenoid drug eruption associated with nivolumab
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2016.11.002
  contributor:
    fullname: Guggina
– volume: 44
  start-page: 117
  year: 2016
  ident: ref_71
  article-title: Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
  publication-title: J. Dermatol.
  doi: 10.1111/1346-8138.13520
  contributor:
    fullname: Nakamura
– volume: 32
  start-page: 1020
  year: 2014
  ident: ref_82
  article-title: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2013.53.0105
  contributor:
    fullname: Topalian
– volume: 76
  start-page: 43
  year: 2016
  ident: ref_112
  article-title: Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
  publication-title: Ann. Rheum. Dis.
  doi: 10.1136/annrheumdis-2016-209595
  contributor:
    fullname: Cappelli
– volume: 4
  start-page: 55
  year: 2016
  ident: ref_103
  article-title: A case report of Grover’s disease from immu-notherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-016-0157-6
  contributor:
    fullname: Uemura
– volume: 15
  start-page: 766
  year: 2016
  ident: ref_146
  article-title: Vitiligo of the Face in a Patient Treated with Vemurafenib for Metastatic Melanoma
  publication-title: J. Drugs Dermatol.
  contributor:
    fullname: Nasca
– volume: 44
  start-page: 381
  year: 2017
  ident: ref_87
  article-title: Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.12876
  contributor:
    fullname: Vivar
– volume: 96
  start-page: 259
  year: 2016
  ident: ref_38
  article-title: Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma
  publication-title: Acta Derm. -Venereol.
  doi: 10.2340/00015555-2212
  contributor:
    fullname: Matsumura
– volume: 6
  start-page: 14
  year: 2018
  ident: ref_110
  article-title: Granulomatous/sarcoid-like lesions asso-ciated with checkpoint inhibitors: A marker of therapy response in a subset of melanoma patients
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-018-0323-0
  contributor:
    fullname: Tetzlaff
– volume: 71
  start-page: 1102
  year: 2014
  ident: ref_118
  article-title: Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2014.09.002
  contributor:
    fullname: Sanlorenzo
– volume: 26
  start-page: 417
  year: 2016
  ident: ref_85
  article-title: Ipilimumab-induced acute generalized exanthematous pus-tulosis in a patient with metastatic melanoma
  publication-title: Melanoma Res.
  doi: 10.1097/CMR.0000000000000261
  contributor:
    fullname: Hwang
– volume: 364
  start-page: 2507
  year: 2011
  ident: ref_16
  article-title: Improved survival with vemurafenib in melanoma with BRAF V600E mutation
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1103782
  contributor:
    fullname: Chapman
– volume: 13
  start-page: 1076
  year: 2018
  ident: ref_111
  article-title: Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2018.04.031
  contributor:
    fullname: Gkiozos
– volume: 28
  start-page: 254
  year: 2016
  ident: ref_56
  article-title: Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
  publication-title: Curr. Opin. Oncol.
  doi: 10.1097/CCO.0000000000000290
  contributor:
    fullname: Sibaud
– volume: 151
  start-page: 102
  year: 2015
  ident: ref_142
  article-title: Pregabalin for the Treatment of Painful Hand-Foot Skin Reaction Associated with Dabrafenib
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2014.2455
  contributor:
    fullname: Lilly
– volume: 41
  start-page: 42
  year: 2018
  ident: ref_50
  article-title: Acute Flare of Bullous Pemphigus with Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0000000000000191
  contributor:
    fullname: Garje
– volume: 35
  start-page: 2781
  year: 2017
  ident: ref_58
  article-title: Phase II Trial of Atezolizumab as First-Line or Subsequent Therapy for Patients with Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.71.9476
  contributor:
    fullname: Peters
– volume: 29
  start-page: 1114
  year: 2011
  ident: ref_148
  article-title: Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
  publication-title: Investig. New Drugs
  doi: 10.1007/s10637-010-9567-3
  contributor:
    fullname: Balagula
– volume: 14
  start-page: 38
  year: 2013
  ident: ref_147
  article-title: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(12)70489-8
  contributor:
    fullname: Shaw
– volume: 14
  start-page: S1166
  year: 2019
  ident: ref_61
  article-title: 21 Checkpoint Inhibitor Combinations Among Themselves and with Chemotherapy
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.09.119
  contributor:
    fullname: Mathias
– volume: 366
  start-page: 707
  year: 2012
  ident: ref_126
  article-title: Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1112302
  contributor:
    fullname: Sosman
– volume: 151
  start-page: 1103
  year: 2015
  ident: ref_15
  article-title: Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination with MEK Inhibitors for Metastatic Melanoma
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2015.1745
  contributor:
    fullname: Carlos
– volume: 69
  start-page: e28
  year: 2013
  ident: ref_145
  article-title: Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2013.01.012
  contributor:
    fullname: Moreno
– volume: 22
  start-page: 399
  year: 2012
  ident: ref_144
  article-title: Vemurafenib-induced neutrophilic panniculitis
  publication-title: Melanoma Res.
  doi: 10.1097/CMR.0b013e3283570792
  contributor:
    fullname: Monfort
– volume: 24
  start-page: 1689
  year: 2015
  ident: ref_161
  article-title: Dysgeusia and weight loss under treatment with vismodegib: Benefit of nutritional management
  publication-title: Support. Care Cancer
  contributor:
    fullname: Jirka
– volume: 20
  start-page: 812
  year: 2015
  ident: ref_7
  article-title: The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2014-0422
  contributor:
    fullname: Pennock
– volume: 35
  start-page: 607
  year: 2021
  ident: ref_10
  article-title: Systematic review of BRAF/MEK inhibitors-induced Severe Cu-taneous Adverse Reactions (SCARs)
  publication-title: J. Eur. Acad. Dermatol. Venereol.
  doi: 10.1111/jdv.16894
– volume: 67
  start-page: 1025
  year: 2012
  ident: ref_26
  article-title: Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2012.02.010
  contributor:
    fullname: Chen
– volume: 128
  start-page: 1286
  year: 2008
  ident: ref_150
  article-title: IGF-1 Induces SREBP-1 Expression and Lipogenesis in SEB-1 Sebocytes via Activation of the Phosphoinositide 3-Kinase/Akt Pathway
  publication-title: J. Investig. Dermatol.
  doi: 10.1038/sj.jid.5701155
  contributor:
    fullname: Smith
– volume: 2
  start-page: 290
  year: 2016
  ident: ref_109
  article-title: Pembrolizumab-associated sarcoidosis
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2016.06.004
  contributor:
    fullname: Cotliar
– volume: 17
  start-page: 57
  year: 2016
  ident: ref_14
  article-title: Cutaneous Complications of Targeted Melanoma Therapy
  publication-title: Curr. Treat. Options Oncol.
  doi: 10.1007/s11864-016-0434-0
  contributor:
    fullname: Kwong
– volume: 43
  start-page: 339
  year: 2016
  ident: ref_31
  article-title: Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.12666
  contributor:
    fullname: Schaberg
– volume: 44
  start-page: 158
  year: 2016
  ident: ref_27
  article-title: Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.12858
  contributor:
    fullname: Curry
– volume: 17
  start-page: 883
  year: 2016
  ident: ref_62
  article-title: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)30098-5
  contributor:
    fullname: Antonia
– volume: 21
  start-page: 409
  year: 2009
  ident: ref_64
  article-title: Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdp325
  contributor:
    fullname: Quaglino
– ident: ref_116
  doi: 10.1186/s12885-017-3313-6
– volume: 33
  start-page: 335
  year: 2020
  ident: ref_29
  article-title: Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review
  publication-title: Acta Med. Port.
  doi: 10.20344/amp.12424
  contributor:
    fullname: Gomes
– volume: 24
  start-page: e1228
  year: 2019
  ident: ref_92
  article-title: Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  publication-title: Oncol.
  doi: 10.1634/theoncologist.2019-0250
  contributor:
    fullname: Raschi
– volume: 2016
  start-page: 1
  year: 2016
  ident: ref_9
  article-title: Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
  publication-title: Dermatol. Res. Pract.
– volume: 22
  start-page: 886
  year: 2016
  ident: ref_72
  article-title: Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-1136
  contributor:
    fullname: Kim
– volume: 39
  start-page: 121
  year: 2017
  ident: ref_33
  article-title: Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features
  publication-title: Am. J. Dermatopathol.
  doi: 10.1097/DAD.0000000000000688
  contributor:
    fullname: Tetzlaff
– volume: 19
  start-page: 1315
  year: 2018
  ident: ref_135
  article-title: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30497-2
  contributor:
    fullname: Dummer
– volume: 149
  start-page: 242
  year: 2013
  ident: ref_165
  article-title: New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2013.1798
  contributor:
    fullname: Aasi
– volume: 4
  start-page: 383
  year: 2016
  ident: ref_49
  article-title: Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-15-0123
  contributor:
    fullname: Naidoo
– volume: 71
  start-page: 217.e1
  year: 2014
  ident: ref_121
  article-title: Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2014.04.013
  contributor:
    fullname: Roh
– volume: 41
  start-page: 214
  year: 2019
  ident: ref_138
  article-title: BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases
  publication-title: Am. J. Dermatopathol.
  doi: 10.1097/DAD.0000000000001276
  contributor:
    fullname: Sinha
– volume: 155
  start-page: 25
  year: 2021
  ident: ref_97
  article-title: Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2021.06.031
  contributor:
    fullname: Coustal
– volume: 10
  start-page: 1259
  year: 2018
  ident: ref_91
  article-title: Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S163391
  contributor:
    fullname: Chen
– volume: 3
  start-page: 90
  year: 2017
  ident: ref_60
  article-title: Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2016.10.008
  contributor:
    fullname: Yin
– volume: 5
  start-page: 216
  year: 2019
  ident: ref_89
  article-title: Nivolumab-associated DRESS syndrome: A case report
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2018.11.017
  contributor:
    fullname: Lu
– ident: ref_160
– volume: 44
  start-page: 1080
  year: 2017
  ident: ref_101
  article-title: Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.13044
  contributor:
    fullname: Tetzlaff
– volume: 153
  start-page: 603
  year: 2017
  ident: ref_48
  article-title: Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2017.0091
  contributor:
    fullname: Sowerby
– volume: 67
  start-page: 1265
  year: 2012
  ident: ref_141
  article-title: Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2012.04.008
  contributor:
    fullname: Chu
– volume: 80
  start-page: 990
  year: 2019
  ident: ref_44
  article-title: Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2018.10.062
  contributor:
    fullname: Coleman
– volume: 151
  start-page: 1206
  year: 2015
  ident: ref_59
  article-title: Pembrolizumab cutaneous adverse events and their asso-ciation with disease progression
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2015.1916
  contributor:
    fullname: Sanlorenzo
– volume: 6
  start-page: 27
  year: 2013
  ident: ref_128
  article-title: Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Ini-tiating Treatment with Vemurafenib
  publication-title: J. Clin. Aesthet. Dermatol.
  contributor:
    fullname: Cohen
– volume: 23
  start-page: 1
  year: 2014
  ident: ref_77
  article-title: Oral health in oncology: Impact of immunotherapy
  publication-title: Support. Care Cancer
  doi: 10.1007/s00520-014-2434-6
  contributor:
    fullname: Jackson
– volume: 11
  start-page: 1
  year: 2022
  ident: ref_158
  article-title: Experience with sonidegib in patients with advanced basal cell carcinoma: Case reports
  publication-title: Drugs Context
  doi: 10.7573/dic.2022-3-8
  contributor:
    fullname: Puig
– volume: 31
  start-page: e464
  year: 2017
  ident: ref_34
  article-title: Oral Lichenoid Reactions associated with anti-PD-1/PD-L1 therapies: Clinicopathological findings
  publication-title: J. Eur. Acad. Dermatol. Venereol.
  doi: 10.1111/jdv.14284
  contributor:
    fullname: Sibaud
– volume: 18
  start-page: 314
  year: 2013
  ident: ref_12
  article-title: Analysis of Dermatologic Events in Vemu-rafenib-Treated Patients with Melanoma
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2012-0333
  contributor:
    fullname: Lacouture
– volume: 11
  start-page: e2021155
  year: 2021
  ident: ref_2
  article-title: Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
  publication-title: Dermatol. Pract. Concept.
  doi: 10.5826/dpc.1101a155
  contributor:
    fullname: Apalla
– volume: 22
  start-page: 4023
  year: 2016
  ident: ref_88
  article-title: Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-2872
  contributor:
    fullname: Goldinger
– volume: 26
  start-page: 2375
  year: 2015
  ident: ref_28
  article-title: Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv383
  contributor:
    fullname: Naidoo
– volume: 26
  start-page: 1762
  year: 2020
  ident: ref_113
  article-title: Sweet’s syndrome under ipilimumab therapy and a brief comparison of the cases in literature
  publication-title: J. Oncol. Pharm. Pract.
  doi: 10.1177/1078155220906885
  contributor:
    fullname: Akkus
– volume: 2
  start-page: 264
  year: 2016
  ident: ref_108
  article-title: Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2016.05.002
  contributor:
    fullname: Suozzi
– volume: 29
  start-page: 2871
  year: 2022
  ident: ref_1
  article-title: Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article
  publication-title: Curr. Oncol.
  doi: 10.3390/curroncol29040234
  contributor:
    fullname: Chen
– volume: 13
  start-page: 175
  year: 2017
  ident: ref_159
  article-title: Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma
  publication-title: Futur. Oncol.
  doi: 10.2217/fon-2016-0296
  contributor:
    fullname: Fife
– ident: ref_84
  doi: 10.1371/journal.pone.0053745
– volume: 36
  start-page: 192
  year: 2014
  ident: ref_122
  article-title: BRAF Inhibitor Induced Verrucal Keratosis
  publication-title: Am. J. Dermatopathol.
  doi: 10.1097/DAD.0b013e3182858142
  contributor:
    fullname: Anforth
– volume: 43
  start-page: 688
  year: 2016
  ident: ref_83
  article-title: Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: A report on bullous skin eruptions
  publication-title: J. Cutan. Pathol.
  doi: 10.1111/cup.12717
  contributor:
    fullname: Jour
– volume: 38
  start-page: e93
  year: 2016
  ident: ref_143
  article-title: Vemuraf-enib-induced neutrophilic panniculitis: A new case and review of the literature
  publication-title: Am. J. Dermatopathol.
  doi: 10.1097/DAD.0000000000000528
  contributor:
    fullname: Aliste
– volume: 148
  start-page: 1183
  year: 2012
  ident: ref_129
  article-title: Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: Importance of sequential dermoscopy
  publication-title: Arch. Dermatol.
  doi: 10.1001/archdermatol.2012.2649
  contributor:
    fullname: Haenssle
– volume: 30
  start-page: 2375
  year: 2012
  ident: ref_132
  article-title: Atypical Melanocytic Proliferations and New Primary Melanomas in Patients with Advanced Melanoma Undergoing Selective BRAF Inhibition
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.41.1660
  contributor:
    fullname: Zimmer
– volume: 83
  start-page: 1255
  year: 2020
  ident: ref_42
  article-title: Immune checkpoint inhibitor–related dermatologic adverse events
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2020.03.132
  contributor:
    fullname: Geisler
– volume: 71
  start-page: 161
  year: 2014
  ident: ref_24
  article-title: Ipilimumab in patients with cancer and the management of dermatologic adverse events
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2014.02.035
  contributor:
    fullname: Lacouture
– volume: 34
  start-page: 441
  year: 2019
  ident: ref_130
  article-title: Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer
  publication-title: Vivo
  doi: 10.21873/invivo.11793
  contributor:
    fullname: Meneguzzo
– volume: 1
  start-page: 82
  year: 2018
  ident: ref_105
  article-title: Pyoderma Gangrenosum Following Initiation of Immune Checkpoint Inhibitor Therapy
  publication-title: J. Immunother. Precis. Oncol.
  doi: 10.4103/JIPO.JIPO_11_18
  contributor:
    fullname: Welborn
– volume: 60
  start-page: 190
  year: 2016
  ident: ref_23
  article-title: Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2016.02.025
  contributor:
    fullname: Hofmann
– volume: 176
  start-page: 1649
  year: 2016
  ident: ref_73
  article-title: Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.15237
  contributor:
    fullname: Zarbo
– volume: 35
  start-page: 785
  year: 2017
  ident: ref_20
  article-title: Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.66.1389
  contributor:
    fullname: Weber
– volume: 19
  start-page: 345
  year: 2018
  ident: ref_5
  article-title: Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy
  publication-title: Am. J. Clin. Dermatol.
  doi: 10.1007/s40257-017-0336-3
  contributor:
    fullname: Sibaud
– volume: 375
  start-page: 2550
  year: 2016
  ident: ref_155
  article-title: Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1605943
  contributor:
    fullname: Dombi
– volume: 6
  start-page: 262
  year: 2019
  ident: ref_52
  article-title: Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy
  publication-title: Front. Med.
  doi: 10.3389/fmed.2019.00262
  contributor:
    fullname: Krammer
– volume: 24
  start-page: 530
  year: 2013
  ident: ref_124
  article-title: Cutaneous effects of BRAF inhibitor therapy: A case series
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mds292
  contributor:
    fullname: Mattei
– volume: 365
  start-page: 1448
  year: 2011
  ident: ref_133
  article-title: Vemurafenib in melanoma with BRAF V600E mutation
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc1108651
  contributor:
    fullname: Morita
– volume: 66
  start-page: e27682
  year: 2019
  ident: ref_156
  article-title: Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study
  publication-title: Pediatr. Blood Cancer
  doi: 10.1002/pbc.27682
  contributor:
    fullname: Song
– volume: 2
  start-page: 442
  year: 2016
  ident: ref_47
  article-title: Development of bullous pemphigoid during nivolumab therapy
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2016.05.009
  contributor:
    fullname: Damsky
– volume: 6
  start-page: 3479
  year: 2015
  ident: ref_6
  article-title: PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2980
  contributor:
    fullname: Luke
– volume: 172
  start-page: 1671
  year: 2015
  ident: ref_157
  article-title: Persistent alopecia induced by vismodegib
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.13630
  contributor:
    fullname: Alkeraye
– volume: 151
  start-page: 78
  year: 2015
  ident: ref_151
  article-title: MEK inhibitor-induced dusky erythema: Characteristic drug hypersensitivity manifestation in 3 patients
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2014.3207
  contributor:
    fullname: Patel
– volume: 386
  start-page: 24
  year: 2022
  ident: ref_22
  article-title: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2109970
  contributor:
    fullname: Tawbi
– volume: 37
  start-page: 795
  year: 2015
  ident: ref_139
  article-title: BRAF Inhibitor-Induced Antitumoral Granu-lomatous Dermatitis Eruption in Advanced Melanoma
  publication-title: Am. J. Dermatopathol.
  doi: 10.1097/DAD.0000000000000281
  contributor:
    fullname: Garrido
– volume: 35
  start-page: 169
  year: 2012
  ident: ref_37
  article-title: PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood from Patients with Prostate and Advanced Melanoma Cancer
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e318247a4e7
  contributor:
    fullname: Dulos
– volume: 10
  start-page: 82
  year: 2021
  ident: ref_54
  article-title: Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2021.02.012
  contributor:
    fullname: McNally
– volume: 19
  start-page: 31
  year: 2018
  ident: ref_75
  article-title: Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
  publication-title: Am. J. Clin. Dermatol.
  doi: 10.1007/s40257-018-0384-3
  contributor:
    fullname: Lacouture
– volume: 35
  start-page: e15607
  year: 2022
  ident: ref_149
  article-title: Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline
  publication-title: Dermatol. Ther.
  contributor:
    fullname: Isoletta
– volume: 72
  start-page: 738
  year: 2015
  ident: ref_136
  article-title: RASopathic alopecia: Hair changes associated with vemu-rafenib therapy
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2015.01.011
  contributor:
    fullname: Piraccini
– volume: 152
  start-page: 1128
  year: 2016
  ident: ref_25
  article-title: Clinical and histologic features of lichenoid mucocu-taneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2016.2226
  contributor:
    fullname: Shi
– volume: 35
  start-page: 76
  year: 2015
  ident: ref_66
  article-title: Managing Immune Checkpoint-Blocking Antibody Side Effects
  publication-title: Am. Soc. Clin. Oncol. Educ. Book
  doi: 10.14694/EdBook_AM.2015.35.76
  contributor:
    fullname: Postow
– volume: 72
  start-page: 221
  year: 2015
  ident: ref_3
  article-title: Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2014.07.033
  contributor:
    fullname: Macdonald
– volume: 97
  start-page: 539
  year: 2017
  ident: ref_115
  article-title: Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer
  publication-title: Acta Derm.-Venereol.
  doi: 10.2340/00015555-2566
  contributor:
    fullname: Bousquet
– volume: 11
  start-page: XD06
  year: 2017
  ident: ref_137
  article-title: Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report
  publication-title: J. Clin. Diagn. Res.
  contributor:
    fullname: Cavalieri
– volume: 33
  start-page: 773
  year: 2015
  ident: ref_70
  article-title: Vitiligo-Like Depigmentation in Patients with Stage III-IV Melanoma Receiving Immunotherapy and Its Association with Survival: A Systematic Review and Meta-Analysis
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2014.57.4756
  contributor:
    fullname: Teulings
– volume: 59
  start-page: e183
  year: 2020
  ident: ref_93
  article-title: Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review
  publication-title: Int. J. Dermatol.
  contributor:
    fullname: Bs
– volume: 172
  start-page: 239
  year: 2014
  ident: ref_123
  article-title: Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.13200
  contributor:
    fullname: Anforth
– volume: 50
  start-page: 1089
  year: 2020
  ident: ref_4
  article-title: Immunotherapy for squamous cell carcinoma of the head and neck
  publication-title: Jpn. J. Clin. Oncol.
  doi: 10.1093/jjco/hyaa139
  contributor:
    fullname: Yokota
– volume: 153
  start-page: 694
  year: 2017
  ident: ref_98
  article-title: Eruptive Keratoacanthomas Associated with Pembrolizumab Therapy
  publication-title: JAMA Dermatol.
  doi: 10.1001/jamadermatol.2017.0989
  contributor:
    fullname: Kwong
– volume: 22
  start-page: S457
  year: 2019
  ident: ref_18
  article-title: PCN111 comparison of adverse event costs of nivolumab+ipilimumab versus sunitinib for previously untreated intermediate-/poor-risk ad-vanced renal cell carcinoma in Switzerland
  publication-title: Value Health
  doi: 10.1016/j.jval.2019.09.308
  contributor:
    fullname: Gooden
– volume: 25
  start-page: 91
  year: 2015
  ident: ref_131
  article-title: Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma
  publication-title: Melanoma Res.
  doi: 10.1097/CMR.0000000000000127
  contributor:
    fullname: Anforth
– volume: 25
  start-page: 59
  year: 2020
  ident: ref_8
  article-title: Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
  publication-title: J. Cutan. Med. Surg.
  doi: 10.1177/1203475420943260
  contributor:
    fullname: Muntyanu
– ident: ref_99
  doi: 10.3390/diagnostics11050747
– volume: 389
  start-page: 255
  year: 2017
  ident: ref_74
  article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32517-X
  contributor:
    fullname: Rittmeyer
– volume: 23
  start-page: 638
  year: 2016
  ident: ref_76
  article-title: Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
  publication-title: J. Oncol. Pharm. Pract.
  doi: 10.1177/1078155216674355
  contributor:
    fullname: Dasanu
– volume: 367
  start-page: 107
  year: 2012
  ident: ref_154
  article-title: Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1203421
  contributor:
    fullname: Flaherty
– volume: 142
  start-page: 176
  year: 2014
  ident: ref_13
  article-title: BRAF inhibitors in cancer therapy
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2013.11.011
– volume: 373
  start-page: 23
  year: 2015
  ident: ref_19
  article-title: Combined Nivolumab and Ipilimumab or Mono-therapy in Untreated Melanoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1504030
  contributor:
    fullname: Larkin
– volume: 372
  start-page: 30
  year: 2015
  ident: ref_134
  article-title: Improved overall survival in melanoma with combined dabrafenib and trametinib
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1412690
  contributor:
    fullname: Robert
– volume: 39
  start-page: 202
  year: 2016
  ident: ref_36
  article-title: Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0000000000000121
  contributor:
    fullname: Chia
– volume: 389
  start-page: 67
  year: 2017
  ident: ref_57
  article-title: Atezolizumab as first-line treatment in cispla-tin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32455-2
  contributor:
    fullname: Balar
– volume: 372
  start-page: 320
  year: 2015
  ident: ref_21
  article-title: Nivolumab in Previously Untreated Melanoma without BRAF Mutation
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1412082
  contributor:
    fullname: Robert
– volume: 23
  start-page: 498
  year: 2013
  ident: ref_114
  article-title: Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy
  publication-title: Melanoma Res.
  doi: 10.1097/CMR.0000000000000017
  contributor:
    fullname: Pintova
– volume: 178
  start-page: 265
  year: 2018
  ident: ref_67
  article-title: A case report of disappearing pigmented skin lesions as-sociated with pembrolizumab treatment for metastatic melanoma
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.15354
  contributor:
    fullname: Wolner
– volume: 108
  start-page: 6
  year: 2017
  ident: ref_153
  article-title: Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management
  publication-title: Actas Dermosifiliogr.
  doi: 10.1016/j.ad.2016.05.019
  contributor:
    fullname: Hwang
– ident: ref_106
  doi: 10.5070/D3274053158
– volume: 171
  start-page: 1236
  year: 2014
  ident: ref_102
  article-title: First report of ipilimumab-induced Grover disease
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.13058
  contributor:
    fullname: Munoz
– volume: 25
  start-page: 569
  year: 2012
  ident: ref_125
  article-title: Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors
  publication-title: Pigment. Cell Melanoma Res.
  doi: 10.1111/j.1755-148X.2012.01031.x
  contributor:
    fullname: Anforth
– volume: 74
  start-page: 455
  year: 2016
  ident: ref_43
  article-title: Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2015.10.029
  contributor:
    fullname: Hwang
– volume: 366
  start-page: 2171
  year: 2012
  ident: ref_17
  article-title: Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1113713
  contributor:
    fullname: Sekulic
– volume: 38
  start-page: 18
  year: 2020
  ident: ref_152
  article-title: Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy
  publication-title: Pediatr. Dermatol.
  doi: 10.1111/pde.14495
  contributor:
    fullname: Carlberg
– volume: 31
  start-page: e254
  year: 2016
  ident: ref_40
  article-title: Anti-PD1-induced psoriasis: A study of 21 patients
  publication-title: J. Eur. Acad. Dermatol. Venereol.
  doi: 10.1111/jdv.14011
  contributor:
    fullname: Bonigen
– volume: 125
  start-page: 259
  year: 2017
  ident: ref_41
  article-title: Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: Immunohistochemical analyses and clinical outcome
  publication-title: Apmis
  doi: 10.1111/apm.12658
  contributor:
    fullname: Abdulkader
– volume: 88
  start-page: 93
  year: 2021
  ident: ref_95
  article-title: Immuno-therapy-intensified paraneoplastic dermatomyositis
  publication-title: Indian J. Dermatol. Venereol. Leprol.
  doi: 10.25259/IJDVL_1306_20
  contributor:
    fullname: Estenaga
– volume: 4
  start-page: 20
  year: 2016
  ident: ref_46
  article-title: Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-016-0123-3
  contributor:
    fullname: Beck
– volume: 24
  start-page: 1691
  year: 2013
  ident: ref_120
  article-title: Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdt015
  contributor:
    fullname: Boussemart
– volume: 31
  start-page: e349
  year: 2017
  ident: ref_55
  article-title: Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor
  publication-title: J. Eur. Acad. Dermatol. Venereol.
  doi: 10.1111/jdv.14143
  contributor:
    fullname: Kwon
– volume: 44
  start-page: 643
  year: 2019
  ident: ref_63
  article-title: Vitiligo-like depigmentation in oncology patients treated with immuno-therapies for nonmelanoma metastatic cancers
  publication-title: Clin. Exp. Dermatol.
  doi: 10.1111/ced.13867
  contributor:
    fullname: Liu
– volume: 79
  start-page: 1081
  year: 2018
  ident: ref_45
  article-title: Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
  publication-title: J. Am. Acad. Dermatol.
  doi: 10.1016/j.jaad.2018.07.008
  contributor:
    fullname: Siegel
– volume: 25
  start-page: 1713
  year: 2017
  ident: ref_78
  article-title: Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint in-hibitors
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-017-3629-4
  contributor:
    fullname: Vigarios
– volume: 13
  start-page: 118
  year: 2021
  ident: ref_100
  article-title: Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2021.05.002
  contributor:
    fullname: Pach
– volume: 4
  start-page: 123
  year: 2018
  ident: ref_163
  article-title: Acute generalized exanthematous pustulosis simulating Stevens-Johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib
  publication-title: JAAD Case Rep.
  doi: 10.1016/j.jdcr.2017.08.001
  contributor:
    fullname: Sendagorta
– volume: 41
  start-page: 125
  year: 2017
  ident: ref_80
  article-title: Cutaneous adverse effects of the immune checkpoint inhibitors
  publication-title: Curr. Probl. Cancer
  doi: 10.1016/j.currproblcancer.2016.12.001
  contributor:
    fullname: Collins
SSID ssj0000331767
Score 2.3625414
SecondaryResourceType review_article
Snippet The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent...
Cutaneous side effects are among the most frequently reported adverse reactions of modern dermato-oncological therapies, such as immune checkpoint inhibitors...
Simple SummaryCutaneous side effects are among the most frequently reported adverse reactions of modern dermato-oncological therapies, such as immune...
SourceID pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 3126
SubjectTerms Analysis
Antimitotic agents
Antineoplastic agents
Cancer
Care and treatment
Cell growth
Chemotherapy
Complications and side effects
Dermatitis
Development and progression
Immune checkpoint inhibitors
Immunology
Immunotherapy
Kinases
Malignancy
Melanoma
Metastases
Mutation
Oncology, Experimental
Patients
Proteins
Pruritus
Psoriasis
Quality of life
Review
Side effects
Skin
Skin cancer
Squamous cell carcinoma
Toxicity
SummonAdditionalLinks – databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVkJcEG8CbWUkJLhETe3EjxPqUwVpqwq2Um-R40fZS3Zptgf-PTOJd9n0wNmOYs1nz8vjbwA-yWiD05XJ0TuIeYkWLre-xGAlctsYbQPvebanl_Liuvx-U92khFuXyirXOrFX1H7hKEd-QDd-xL8vy6_L3zl1jaLb1dRC4zHscIwUignsHJ9dXv3YZFkKgfZRqoHTR2B8f-BImHcdGTpxSJQKW-booVLeskrjisktE3T-HJ4l35EdDWC_gEehfQlPpul2_BUsT-7R1QsYy7Ofcx_YwEzcsUVkQ8szNuvrvoNns4FMgNnWs2_0RCQ9xPrD5i27GrhWO0ZJWnZKunu11pFsio777dDTt3sN1-dns5OLPHVUyF2pzSr3UhrlDQLguFCx8Y7Hiji_XEW87956XRjbKHT7GqsKJyWOxBIBbQQvLBdvYNIu2vAOmFVV0NEKo6VGiKONinsnnNG6bCIPGXxZC7ZeDsQZNQYchEH9AIMMPpPgazpSKF1n08sA_BGRU9VHCoNYhX6nymB3NBOPghsPr6Gr01Hs6n8bJ4OPm2H6ksrLelBqYkGjKyheZPB2QHqzaKGEQj2Iq9SjPbCZQATd45F2_qsn6kbnDfXboXj__3V9gKfUxL4vQDO7MFnd3Yc9dHVWzX7az38BzDoB5Q
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9VAEB60gvgi3o1WWUHQl2i6u9nLg0ipliocETwH-hY2e6kHJK0np2D_vTPZnGNTis-byzLfZuab7Ow3AK9VctGb2pbIDlIpMcKVLkhMVhJ3rTUu8kFne_ZNHS3k1-P6-F87oNGA_bWpHfWTWqx-vfvz--IjfvAfKOPElP29J_useopdYo-rm3CLS0zTqY5v5PqDWxYYKoeOsrzSvFTKyiz1c90zJlHqqq--FKymhZSXItPhPbg7Ukq2n9fAfbgRuwdwezZumj-Es4NzZIARU3z2Yxkiy4LFPTtNLHdCY_OhHDwGNs8aA8x1gX2hkyPj-awLtuzY9yzB2jP6d8s-kUtfb1wnmyGfP8mtfvtHsDj8PD84KsdGC6WXxq7LgMbQwSIungud2uB5qkkKzNckBx9cMJV1rUY22DpdeaVwJEnEuRW8clw8hp3utItPgTldR5OcsEYZRD65pHnwwltjZJt4LODtxrDNWdbTaDAPIQyaKxgU8IYM3xD2aF3vxgMD-CLSrGr2Nea2GumoLmB3ciV-IX46vIGu2SywhnaQqZ-DkgW82g7TnVR1NoDSkDga7UzxqoAnGentpIUWGt0jztJM1sD2AtLtno50y5-DfjdyOnR7e-LZ_6f9HO5Qb_uhLs3uws56dR5fIANaty-Hlf0X6JwF9A
  priority: 102
  providerName: Scholars Portal
Title Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
URI https://www.ncbi.nlm.nih.gov/pubmed/37370736
https://www.proquest.com/docview/2829780564
https://search.proquest.com/docview/2830665720
https://pubmed.ncbi.nlm.nih.gov/PMC10296313
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB41RUJcEG8MJVokJLi4Sbz2Po4ltBQkVxGkUm7Weh8QibpRnR767zvjRxT3yMWX8cqrmdl5eGe-AfgkgvFWZTrG6CDEKXq42LgUk5WQmFIr45MGZzu_EOeX6c9VtjoA0ffCNEX7tlwfV_-ujqv136a2cnNlJ32d2GSRz9Epot7M-GQEI9TQvRy9sb8cfaKQLY4Px5x-YomBNzU5Nz4jGIU9F_TQEO95omGV5J7bOXsGT7t4kZ20-3oOB756AY_z7kb8JWzmtxjeeczf2e-186xFI67ZdWDtmDO2bGq9vWPLFkCAmcqxH9QW0jVf3bF1xRYtvmrN6Mcs-0b2etvbRZZjsP6nneNbv4LLs9Pl_DzupijENlV6GzshtHQamW4TLkPpbBIywvmyGWG9O-PUVJtSYqhXGjm1QiAlpCjEkidTk_DXcFhdV_4tMCMzr4LhWgmFYg0myMRZbrVSaRkSH8GXnrHFpgXLKDDJIBkUD2QQwWdifEHHCLlrTdcNgB8iQKriRGLiKjHWlBEcDd5E9bdDci-6ojt-dUHXwzSsQaQRfNyRaSWVlDVCKQj5jK6dkmkEb1pJ7zbNJZdo-3CXaqADuxcIlHtIQV1twLl73Xz3_0vfwxMaat8UpOkjONze3PoPGPpsyzE8-np6sfg1htH31QyfearGjfbfA8OcC3M
link.rule.ids 230,315,730,783,787,888,2228,21400,24330,27936,27937,33756,33757,43817,53804,53806,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaglYALKq8SaMFISHCJmtqJH6eqLa220F1VsJV6ixw_YC_Zpdke-PfMxN5l0wNnO4o1nz0vj78h5KMIxltV6Ry8g5CXYOFy40oIVgIzjVbGs55nezwRo-vy6011kxJuXSqrXOnEXlG7ucUc-QHe-CH_viiPFr9z7BqFt6uphcZDso1UVRB8bZ-cTa6-r7MsBQf7KGTk9OEQ3x9YFOZth4aOHyKlwoY5uq-UN6zSsGJywwSd75CnyXekxxHsZ-SBb5-TR-N0O_6CLE7vwNXzEMvTHzPnaWQm7ug80NjyjE77um_v6DSSCVDTOnqBT0TSQ6w_dNbSq8i12lFM0tIvqLuXKx1Jx-C4_4w9fbuX5Pr8bHo6ylNHhdyWSi9zJ4SWTgMAlnEZGmdZqJDzy1bI--6MU4U2jQS3rzGysELASCgB0IazwjD-imy189a_JtTIyqtguFZCAcTBBMmc5VYrVTaB-Yx8Xgm2XkTijBoCDsSgvodBRj6h4Gs8UiBda9LLAPgRklPVxxKCWAl-p8zI3mAmHAU7HF5BV6ej2NX_Nk5GPqyH8UssL-tBqZEFDa-gWJGR3Yj0etFccgl6EFapBntgPQEJuocj7exXT9QNzhvot0P-5v_rek8ej6bjy_ryYvLtLXmCDe37YjS9R7aWt3d-H9yeZfMu7e2_MG4E3w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVqq4VC2vhhYwEhJcok3jxHZOqLRdtcCuVrCVeoscP2Av2W2zPfDvmUm8200PnO0o1nzjedjjbwA-Cq-dUXkRY3Tg4ww9XKxthsmKT3VVKO3Slmd7PBGX19m3m_wm1D81oaxybRNbQ20Xhs7Ih3TjR_z7Ihv6UBYxPR99Wd7G1EGKblpDO42nsCMzwZMB7Hy9mEx_bk5cEo6-UsiO34djrj80JNi7hpwePyF6hS3X9NhAb3mofvXkljsa7cNeiCPZaQf8ATxx9XPYHYeb8hewPLvHsM9hXs9-za1jHUtxwxaede3P2KytAXeWzTpiAaZry67ouUh4lPWXzWs27XhXG0YHtuyc7PhqbS_ZGIP4311_3-YlXI8uZmeXceiuEJtMFavYClFIWyAYJuXSV9akPif-L5MTB7zVViWFriSGgJWWiRECR3yG4FY8TXTKX8GgXtTuEJiWuVNe80IJhXB77WVqDTeFUlnlUxfB57Vgy2VHolFi8kEYlI8wiOATCb6k7YXSNTq8EsAfEVFVeSoxoZUYg8oIjnszcVuY_vAaujJsy6Z8UKIIPmyG6UsqNWtBKYkRja6j0iSC1x3Sm0VzySXaRFyl6unAZgKRdfdH6vmflrQbAzm0dSf8zf_X9R52Ua3LH1eT70fwjHrbt3VpxTEMVnf37i1GQKvqXVDtfyZDCQ0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cutaneous+Side+Effects+of+Modern+Targeted+Therapy+and+Immunotherapy+in+Patients+with+Dermatological+Malignancies&rft.jtitle=Cancers&rft.au=Plachouri%2C+Kerasia-Maria&rft.au=Florou%2C+Vaia&rft.au=Georgiou%2C+Vasileios&rft.au=Georgiou%2C+Sophia&rft.date=2023-06-09&rft.pub=MDPI+AG&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=15&rft.issue=12&rft_id=info:doi/10.3390%2Fcancers15123126&rft.externalDocID=A754975667
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon